First report of an extensively drug-resistant VIM-2 metallo-β- lactamase-producing Brevundimonas diminuta clinical isolate

Journal of Clinical Microbiology

Volumn 50, Issue 8, 2012, Pages 2830-2832

  Almuzara, Marisa N ^a   Barberis, Claudia M ^a   Rodríguez, Carlos H ^a   Famiglietti, Angela M R ^a   Ramirez, Maria S ^b   Vaya, Carlos A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Facultad de Medicina ^*  (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; AZTREONAM; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; GENTAMICIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; METALLO BETA LACTAMASE VIM 2; METHYLPREDNISOLONE; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; POVIDONE IODINE; PREDNISONE; RNA 16S; SULTAMICILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACKACHE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BREVUNDIMONAS; BREVUNDIMONAS DIMINUTA; BREVUNDIMONAS VESICULARIS; CASE REPORT; DEATH; ELECTROMYOGRAM; ENZYME SYNTHESIS; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPROMISED PATIENT; LEG ULCER; LIMB WEAKNESS; LOW BACK PAIN; LUPUS ERYTHEMATOSUS NEPHRITIS; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PYODERMA GANGRENOSUM; RNA SEQUENCE; SENSORIMOTOR NEUROPATHY; SEPTIC SHOCK; SUPERINFECTION; WALKING DIFFICULTY;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CAULOBACTERACEAE; DNA, BACTERIAL; DNA, RIBOSOMAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, DNA;

BREVUNDIMONAS DIMINUTA;

EID: 84864413280     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00924-12     Document Type: Article

References (15)

1. Almuzara MN, et al. 2007. VIM-2-producing Pseudomonas putida, Buenos Aires. Emerg. Infect. Dis. 13:668-669.
2. Almuzara MN, et al. 2010. First case of human infection due to Pseudomonas fulva, an environmental bacterium isolated from cerebrospinal fluid. J. Clin. Microbiol. 48:660-664.
3. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; M100-S18, 18th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Han XY, Andrade RA. 2005. Brevundimonas diminuta infections and its resistance to fluoroquinolones. J. Antimicrob. Chemother. 55:853-859. (Pubitemid 40883167)
5. Lee K, Lim YS, Yong D, Yum JH, Chong Y. 2003. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J. Clin. Microbiol. 41:4623-4629. (Pubitemid 37259767)
6. LipumaJJ, Currie B, Peacock SJ,VandammeP. 2011. Burkholderia, Stenotrophomonas, Ralstonia, Cupriavidus, Pandoraea, Brevundimonas, Comamonas, Delftia, and Acidovorax, p 692-713. In Versalovic J, et al. (ed), Manual of clinical microbiology, 10th ed.ASMPress, Washington, DC.
7. Mazzola PG, Martins AM, Penna TC. 2006. Chemical resistance of the Gram-negative bacteria to different sanitizers in a water purification system. BMC Infect. Dis. 6:131-142.
8. Melano R, et al. 2003. Multiple antibiotic-resistance mechanisms including a novel combination of extended-spectrum β-lactamases in a Klebsiella pneumoniae clinical strain isolated in Argentina. J. Antimicrob. Chemother. 52:36-42. (Pubitemid 36850082)
9. Menuet M, et al. 2008. First isolation of two colistin-resistant emerging pathogens, Brevundimonas diminuta and Ochrobactrum anthropi, in a woman with cystic fibrosis: a case report. J. Med. Case Rep. 2:373.
10. Pandit RT. 2012. Brevundimonas diminuta keratitis. Eye Contact Lens 38:63-65.
11. Poirel L, et al. 2000. Characterization of VIM-2, a carbapenemhydrolyzing metallo-β-lactamase and its plasmid-and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother. 44:891-897. (Pubitemid 30165266)
12. VIM-2 in an environmental isolate of Pseudomonas pseudoalcaligenes. Antimicrob. Agents Chemother. 49:2140-2141.
13. Scotta C, et al. 2011. Environmental microbiota represents a natural reservoir for dissemination of clinically relevant metallo-beta-lactamases. Antimicrob. Agents Chemother. 55:5376-5379.
14. Walsh RT, Toleman MA, Poirel L, Nordmann P. 2005. Metallo-β- lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18:306-325.
15. Weisburg WG, Barns SM, Pelletier DA, Lane LD. 1991. 16S ribosomal DNA amplification for phylogenetic study. J. Bacteriol. 173:697-703.